{"id":"ngx-4010-8-capsaicin-patch","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Skin irritation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The activation of TRPV1 receptors by capsaicin leads to the release of neurotransmitters that inhibit pain signals to the brain. NGX-4010 is designed to provide long-lasting pain relief for conditions such as postherpetic neuralgia.","oneSentence":"NGX-4010, an 8% capsaicin patch, works by activating TRPV1 receptors to reduce pain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:06.983Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Postherpetic neuralgia"}]},"trialDetails":[{"nctId":"NCT01713426","phase":"PHASE4","title":"A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2012-07-11","conditions":"Non-diabetic Painful Peripheral Polyneuropathy, Postherpetic Neuralgia (PHN), Peripheral Nerve Injury (PNI)","enrollment":568},{"nctId":"NCT02171182","phase":"","title":"A Study of Efficacy and Safety of Qutenza in Patients With Post-operative Peripheral Neuropathic Pain","status":"COMPLETED","sponsor":"Astellas Pharma s.r.o.","startDate":"2014-01","conditions":"Post-operative Peripheral Neuropathic Pain","enrollment":319},{"nctId":"NCT00321672","phase":"PHASE3","title":"Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy","status":"COMPLETED","sponsor":"NeurogesX","startDate":"2006-06","conditions":"Pain, HIV Infections, Peripheral Nervous System Diseases","enrollment":494},{"nctId":"NCT00916942","phase":"PHASE2","title":"Study of NGX-4010 With the Use of Open Label Lidocaine (2.5%)/Prilocaine (2.5%) Cream for the Treatment of Postherpetic Neuralgia (PHN)","status":"COMPLETED","sponsor":"NeurogesX","startDate":"2009-06","conditions":"Postherpetic Neuralgia","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["the brandname of NGX-4010, 8% capsaicin patch is Qutenza.","The brandname of NGX-4010, 8% capsaicin patch is Qutenza."],"phase":"phase_3","status":"active","brandName":"NGX-4010, 8% capsaicin patch","genericName":"NGX-4010, 8% capsaicin patch","companyName":"NeurogesX","companyId":"neurogesx","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NGX-4010, an 8% capsaicin patch, works by activating TRPV1 receptors to reduce pain. Used for Postherpetic neuralgia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}